Novo Nordisk's newly approved Ozempic will compete directly with Eli Lilly and Co.'s Trulicity in the diabetes drug market. The new drug will be priced at about $676 per prescription, which the company said is on par with other drugs in the class.
Novo Nordisk takes on Lilly with newly approved diabetes drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.